Table 2.

Change in visual acuity from baseline over 5 years following commencement of anti-VEGF therapy

Baseline visual acuity (ETDRS letters)	BRVO					CRVO
	N	Mean (95% CI)	P value	N	Mean (95% CI)	P value
<35	2	36.0 (8.7 to 48.7)	0.05	2	27 (15.0 to 39.0)	0.02
≥35 and<60	8	23.9 (13.5 to 31.5)	0.03	20	15.2 (2.1 to 31.5)	0.02
≥60 and<70	7	14.9 (6.9 to 21.6)	0.03	9	5.75 (8.9 to 20.9)	0.01
≥70 and<85	14	5.1 (4.8 to 12.1)	0.02	6	8.3 (3.0 to 14.6)	0.05
≥85	0	–	–	0	–	–

BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; ETDRS, Early Treatment Diabetic Retinopathy Study; VEGF, vascular endothelial growth factor.